decorative background image

The Potential Role for PARP Inhibitors in Prostate Cancer

Precision oncology involves matching molecular aspects of a tumor to drugs targeting those pathways and is a routine consideration for patients with lung, ovarian, breast, colon, and hematologic cancers. PCa may be next with the use of Poly (ADP-ribose) Polymerase (PARP) inhibitors for patients with genetic defects in pathways regulating DNA repair, dominated by Breast Cancer Gene 2, Breast Cancer Gene 1, and Mutated in Ataxis Telangieectasia alterations.

Read more.


Source: Renal and Urology News

Share